Loading…

Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy

Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventri...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nuclear cardiology 2022-04, Vol.29 (2), p.581-589
Main Authors: Jones, K.A., Small, A.D., Ray, S., Hamilton, D.J., Martin, W., Robinson, J., Goodfield, N.E.R., Paterson, C.A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23
cites cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23
container_end_page 589
container_issue 2
container_start_page 581
container_title Journal of nuclear cardiology
container_volume 29
creator Jones, K.A.
Small, A.D.
Ray, S.
Hamilton, D.J.
Martin, W.
Robinson, J.
Goodfield, N.E.R.
Paterson, C.A.
description Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function. In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups. The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.
doi_str_mv 10.1007/s12350-020-02277-z
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071358123002544</els_id><sourcerecordid>2648552081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</originalsourceid><addsrcrecordid>eNp9UV1rFTEQDaLYWv0DPkjA59V8bDZZEEGKX1AQij6H3GR2b-p2sya7l97-eud2a21f-pDkwJxzZjKHkNecveOM6feFC6lYxcThCK2r6yfkmCspqkYp_hQx07ySyvAj8qKUC8ZYK9v2OTmSQtdGaHNMducuxDQufogB6A7GOUe_DKnPbtru6bR1Bagb3bAvsdAuZZpj-U3LnN0cu-jxTiNNHZ0QobrQZQyQ-xTHnnqX0XxOV9EjHj1kOm8BnfcvybPODQVe3b4n5NeXzz9Pv1VnP75-P_10Vnkl9Fw1IJ2XqgmGeWmCb_QmAPMK6hC00TXjG-U3TIHCmq8lsFBLp1TTQOchCHlCPq6-07K5hOAP_3ODnXK8dHlvk4v2YWWMW9unnTVtKzXXaPD21iCnPwuU2V6kJeM-ihVNbZQSzHBkiZXlcyolQ3fXgTN7yMquWVnMyt5kZa9R9Ob-bHeSf-EgQa6EgqWxh_y_96O2H1YV4F53EVXFYzK4jpjBzzak-Jj8L4UEuTY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2648552081</pqid></control><display><type>article</type><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><source>Springer Nature</source><creator>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</creator><creatorcontrib>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</creatorcontrib><description>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function. In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups. The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</description><identifier>ISSN: 1071-3581</identifier><identifier>EISSN: 1532-6551</identifier><identifier>DOI: 10.1007/s12350-020-02277-z</identifier><identifier>PMID: 32748278</identifier><language>eng</language><publisher>Cham: Elsevier Inc</publisher><subject>Breast cancer ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - drug therapy ; Cancer therapies ; Cardiology ; Cardiotoxicity ; diagnostic and prognostic application ; dyssynchrony ; Ejection fraction ; Entropy ; Female ; Heart Diseases ; Humans ; image analysis ; Imaging ; Medical diagnosis ; Medicine ; Medicine &amp; Public Health ; Nuclear Medicine ; Original ; Original Article ; Radiology ; Radionuclide Ventriculography ; Retrospective Studies ; Risk Assessment ; RNA: planar ; Stroke Volume ; Ventricular Dysfunction, Left - chemically induced ; Ventricular Dysfunction, Left - diagnostic imaging ; Ventricular Function, Left</subject><ispartof>Journal of nuclear cardiology, 2022-04, Vol.29 (2), p.581-589</ispartof><rights>2022 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology</rights><rights>The Author(s) 2020</rights><rights>2020. The Author(s).</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</citedby><cites>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</cites><orcidid>0000-0001-9109-4812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32748278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, K.A.</creatorcontrib><creatorcontrib>Small, A.D.</creatorcontrib><creatorcontrib>Ray, S.</creatorcontrib><creatorcontrib>Hamilton, D.J.</creatorcontrib><creatorcontrib>Martin, W.</creatorcontrib><creatorcontrib>Robinson, J.</creatorcontrib><creatorcontrib>Goodfield, N.E.R.</creatorcontrib><creatorcontrib>Paterson, C.A.</creatorcontrib><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><title>Journal of nuclear cardiology</title><addtitle>J. Nucl. Cardiol</addtitle><addtitle>J Nucl Cardiol</addtitle><description>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function. In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups. The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer therapies</subject><subject>Cardiology</subject><subject>Cardiotoxicity</subject><subject>diagnostic and prognostic application</subject><subject>dyssynchrony</subject><subject>Ejection fraction</subject><subject>Entropy</subject><subject>Female</subject><subject>Heart Diseases</subject><subject>Humans</subject><subject>image analysis</subject><subject>Imaging</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Nuclear Medicine</subject><subject>Original</subject><subject>Original Article</subject><subject>Radiology</subject><subject>Radionuclide Ventriculography</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>RNA: planar</subject><subject>Stroke Volume</subject><subject>Ventricular Dysfunction, Left - chemically induced</subject><subject>Ventricular Dysfunction, Left - diagnostic imaging</subject><subject>Ventricular Function, Left</subject><issn>1071-3581</issn><issn>1532-6551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UV1rFTEQDaLYWv0DPkjA59V8bDZZEEGKX1AQij6H3GR2b-p2sya7l97-eud2a21f-pDkwJxzZjKHkNecveOM6feFC6lYxcThCK2r6yfkmCspqkYp_hQx07ySyvAj8qKUC8ZYK9v2OTmSQtdGaHNMducuxDQufogB6A7GOUe_DKnPbtru6bR1Bagb3bAvsdAuZZpj-U3LnN0cu-jxTiNNHZ0QobrQZQyQ-xTHnnqX0XxOV9EjHj1kOm8BnfcvybPODQVe3b4n5NeXzz9Pv1VnP75-P_10Vnkl9Fw1IJ2XqgmGeWmCb_QmAPMK6hC00TXjG-U3TIHCmq8lsFBLp1TTQOchCHlCPq6-07K5hOAP_3ODnXK8dHlvk4v2YWWMW9unnTVtKzXXaPD21iCnPwuU2V6kJeM-ihVNbZQSzHBkiZXlcyolQ3fXgTN7yMquWVnMyt5kZa9R9Ob-bHeSf-EgQa6EgqWxh_y_96O2H1YV4F53EVXFYzK4jpjBzzak-Jj8L4UEuTY</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Jones, K.A.</creator><creator>Small, A.D.</creator><creator>Ray, S.</creator><creator>Hamilton, D.J.</creator><creator>Martin, W.</creator><creator>Robinson, J.</creator><creator>Goodfield, N.E.R.</creator><creator>Paterson, C.A.</creator><general>Elsevier Inc</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9109-4812</orcidid></search><sort><creationdate>20220401</creationdate><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><author>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer therapies</topic><topic>Cardiology</topic><topic>Cardiotoxicity</topic><topic>diagnostic and prognostic application</topic><topic>dyssynchrony</topic><topic>Ejection fraction</topic><topic>Entropy</topic><topic>Female</topic><topic>Heart Diseases</topic><topic>Humans</topic><topic>image analysis</topic><topic>Imaging</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Nuclear Medicine</topic><topic>Original</topic><topic>Original Article</topic><topic>Radiology</topic><topic>Radionuclide Ventriculography</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>RNA: planar</topic><topic>Stroke Volume</topic><topic>Ventricular Dysfunction, Left - chemically induced</topic><topic>Ventricular Dysfunction, Left - diagnostic imaging</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, K.A.</creatorcontrib><creatorcontrib>Small, A.D.</creatorcontrib><creatorcontrib>Ray, S.</creatorcontrib><creatorcontrib>Hamilton, D.J.</creatorcontrib><creatorcontrib>Martin, W.</creatorcontrib><creatorcontrib>Robinson, J.</creatorcontrib><creatorcontrib>Goodfield, N.E.R.</creatorcontrib><creatorcontrib>Paterson, C.A.</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of nuclear cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, K.A.</au><au>Small, A.D.</au><au>Ray, S.</au><au>Hamilton, D.J.</au><au>Martin, W.</au><au>Robinson, J.</au><au>Goodfield, N.E.R.</au><au>Paterson, C.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</atitle><jtitle>Journal of nuclear cardiology</jtitle><stitle>J. Nucl. Cardiol</stitle><addtitle>J Nucl Cardiol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>29</volume><issue>2</issue><spage>581</spage><epage>589</epage><pages>581-589</pages><issn>1071-3581</issn><eissn>1532-6551</eissn><abstract>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function. In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups. The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</abstract><cop>Cham</cop><pub>Elsevier Inc</pub><pmid>32748278</pmid><doi>10.1007/s12350-020-02277-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9109-4812</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1071-3581
ispartof Journal of nuclear cardiology, 2022-04, Vol.29 (2), p.581-589
issn 1071-3581
1532-6551
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993717
source Springer Nature
subjects Breast cancer
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - drug therapy
Cancer therapies
Cardiology
Cardiotoxicity
diagnostic and prognostic application
dyssynchrony
Ejection fraction
Entropy
Female
Heart Diseases
Humans
image analysis
Imaging
Medical diagnosis
Medicine
Medicine & Public Health
Nuclear Medicine
Original
Original Article
Radiology
Radionuclide Ventriculography
Retrospective Studies
Risk Assessment
RNA: planar
Stroke Volume
Ventricular Dysfunction, Left - chemically induced
Ventricular Dysfunction, Left - diagnostic imaging
Ventricular Function, Left
title Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A57%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radionuclide%20ventriculography%20phase%20analysis%20for%20risk%20stratification%20of%20patients%20undergoing%20cardiotoxic%20cancer%20therapy&rft.jtitle=Journal%20of%20nuclear%20cardiology&rft.au=Jones,%20K.A.&rft.date=2022-04-01&rft.volume=29&rft.issue=2&rft.spage=581&rft.epage=589&rft.pages=581-589&rft.issn=1071-3581&rft.eissn=1532-6551&rft_id=info:doi/10.1007/s12350-020-02277-z&rft_dat=%3Cproquest_pubme%3E2648552081%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2648552081&rft_id=info:pmid/32748278&rfr_iscdi=true